1009 related articles for article (PubMed ID: 32843065)
1. Upregulation of METTL14 mediates the elevation of PERP mRNA N
Wang M; Liu J; Zhao Y; He R; Xu X; Guo X; Li X; Xu S; Miao J; Guo J; Zhang H; Gong J; Zhu F; Tian R; Shi C; Peng F; Feng Y; Yu S; Xie Y; Jiang J; Li M; Wei W; He C; Qin R
Mol Cancer; 2020 Aug; 19(1):130. PubMed ID: 32843065
[TBL] [Abstract][Full Text] [Related]
2. CLK1/SRSF5 pathway induces aberrant exon skipping of METTL14 and Cyclin L2 and promotes growth and metastasis of pancreatic cancer.
Chen S; Yang C; Wang ZW; Hu JF; Pan JJ; Liao CY; Zhang JQ; Chen JZ; Huang Y; Huang L; Zhan Q; Tian YF; Shen BY; Wang YD
J Hematol Oncol; 2021 Apr; 14(1):60. PubMed ID: 33849617
[TBL] [Abstract][Full Text] [Related]
3. METTL14-mediated N6-methyladenosine modification of SOX4 mRNA inhibits tumor metastasis in colorectal cancer.
Chen X; Xu M; Xu X; Zeng K; Liu X; Pan B; Li C; Sun L; Qin J; Xu T; He B; Pan Y; Sun H; Wang S
Mol Cancer; 2020 Jun; 19(1):106. PubMed ID: 32552762
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone deacetylase suppresses tumor growth through eliciting METTL14-modified m
Zhuang A; Gu X; Ge T; Wang S; Ge S; Chai P; Jia R; Fan X
Cancer Commun (Lond); 2023 Nov; 43(11):1185-1206. PubMed ID: 37466203
[TBL] [Abstract][Full Text] [Related]
5. METTL14-mediated N
Liu Z; Sun T; Piao C; Zhang Z; Kong C
Cell Commun Signal; 2022 Mar; 20(1):36. PubMed ID: 35305660
[TBL] [Abstract][Full Text] [Related]
6. METTL14-mediated epitranscriptome modification of MN1 mRNA promote tumorigenicity and all-trans-retinoic acid resistance in osteosarcoma.
Li HB; Huang G; Tu J; Lv DM; Jin QL; Chen JK; Zou YT; Lee DF; Shen JN; Xie XB
EBioMedicine; 2022 Aug; 82():104142. PubMed ID: 35810559
[TBL] [Abstract][Full Text] [Related]
7. Downregulated METTL14 accumulates BPTF that reinforces super-enhancers and distal lung metastasis via glycolytic reprogramming in renal cell carcinoma.
Zhang C; Chen L; Liu Y; Huang J; Liu A; Xu Y; Shen Y; He H; Xu D
Theranostics; 2021; 11(8):3676-3693. PubMed ID: 33664855
[No Abstract] [Full Text] [Related]
8. piRNA-14633 promotes cervical cancer cell malignancy in a METTL14-dependent m6A RNA methylation manner.
Xie Q; Li Z; Luo X; Wang D; Zhou Y; Zhao J; Gao S; Yang Y; Fu W; Kong L; Sun T
J Transl Med; 2022 Jan; 20(1):51. PubMed ID: 35093098
[TBL] [Abstract][Full Text] [Related]
9. METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP.
Ma Z; Li Q; Liu P; Dong W; Zuo Y
Cell Biol Int; 2020 Dec; 44(12):2524-2531. PubMed ID: 32869897
[TBL] [Abstract][Full Text] [Related]
10. METTL14 promotes glomerular endothelial cell injury and diabetic nephropathy via m6A modification of α-klotho.
Li M; Deng L; Xu G
Mol Med; 2021 Sep; 27(1):106. PubMed ID: 34503454
[TBL] [Abstract][Full Text] [Related]
11. Methyltransferase-like (METTL)14-mediated N6-methyladenosine modification modulates retinal pigment epithelial (RPE) activity by regulating the methylation of microtubule-associated protein (MAP)2.
Yin L; Ma C; Hou S; Ma X
Bioengineered; 2022 Mar; 13(3):4773-4785. PubMed ID: 35139773
[TBL] [Abstract][Full Text] [Related]
12. METTL3/METTL14 Transactivation and m
Feng Y; Dong H; Sun B; Hu Y; Yang Y; Jia Y; Jia L; Zhong X; Zhao R
Cell Mol Gastroenterol Hepatol; 2021; 12(3):839-856. PubMed ID: 33992834
[TBL] [Abstract][Full Text] [Related]
13. N(6)-adenosine-methyltransferase-14 promotes glioma tumorigenesis by repressing argininosuccinate synthase 1 expression in an m6A-dependent manner.
Miao YQ; Chen W; Zhou J; Shen Q; Sun Y; Li T; Wang SC
Bioengineered; 2022 Jan; 13(1):1858-1871. PubMed ID: 35012429
[TBL] [Abstract][Full Text] [Related]
14. Identification of three m6A-related mRNAs signature and risk score for the prognostication of hepatocellular carcinoma.
Li Z; Li F; Peng Y; Fang J; Zhou J
Cancer Med; 2020 Mar; 9(5):1877-1889. PubMed ID: 31943856
[TBL] [Abstract][Full Text] [Related]
15. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6‑methyladenosine and hsa‑miR‑146a‑5p expression.
Yi D; Wang R; Shi X; Xu L; Yilihamu Y; Sang J
Oncol Rep; 2020 May; 43(5):1375-1386. PubMed ID: 32323801
[TBL] [Abstract][Full Text] [Related]
16. YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer.
Li J; Xie H; Ying Y; Chen H; Yan H; He L; Xu M; Xu X; Liang Z; Liu B; Wang X; Zheng X; Xie L
Mol Cancer; 2020 Oct; 19(1):152. PubMed ID: 33121495
[TBL] [Abstract][Full Text] [Related]
17. Functions, mechanisms, and therapeutic implications of METTL14 in human cancer.
Guan Q; Lin H; Miao L; Guo H; Chen Y; Zhuo Z; He J
J Hematol Oncol; 2022 Feb; 15(1):13. PubMed ID: 35115038
[TBL] [Abstract][Full Text] [Related]
18. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST.
Yang X; Zhang S; He C; Xue P; Zhang L; He Z; Zang L; Feng B; Sun J; Zheng M
Mol Cancer; 2020 Feb; 19(1):46. PubMed ID: 32111213
[TBL] [Abstract][Full Text] [Related]
19. Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
Liu X; Qin J; Gao T; Li C; Chen X; Zeng K; Xu M; He B; Pan B; Xu X; Pan Y; Sun H; Xu T; Wang S
Aging (Albany NY); 2020 Nov; 12(21):21638-21659. PubMed ID: 33159022
[TBL] [Abstract][Full Text] [Related]
20. Changes of N6-methyladenosine modulators promote breast cancer progression.
Wu L; Wu D; Ning J; Liu W; Zhang D
BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
